Rein Therapeutics Reports Blinded RENEW Data and Q3 2026 Results
Rein Therapeutics reported preliminary blinded Phase 2 RENEW data showing Week 12 FVC improvement in 33% of evaluable patients and $36.5 million in cash, equivalents and marketable securities.Key Highlights:Original SEC Filing: Rein Therapeutics, Inc. [ RNTX ] - 8-K - Nov. 16, 2026This is an AI-pow…